TANVEX BIOPHARMA USA, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Phase 3

Completed

Conditions: Breast Neoplasms
Early-stage Breast Cancer
Breast Cancer
HER2-positive Breast Cancer
Stage II Breast Cancer
Stage IIIA Breast Cancer

Interventions: Biological: TX05 (trastuzumab)
Biological: Herceptin (trastuzumab)

First Posted Date: 2019-09-30

Last Posted Date: 2022-10-26

Lead Sponsor: Tanvex BioPharma USA, Inc.

Target Recruit Count: 338

Registration Number: NCT04109391

Locations: 🇧🇾
Tanvex Investigational Site 1002E, Minsk, Belarus
🇧🇾
Tanvex Investigational Site 1005E, Mogilev, Belarus
🇬🇪
Tanvex Investigational Site 5001E, Tbilisi, Georgia

and more 83 locations

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

Phase 3

Completed

Conditions: Stage II Breast Cancer
Stage IIIA Breast Cancer
Breast Cancer
Breast Neoplasms
HER2-positive Breast Cancer

Interventions: Biological: Herceptin®
Biological: TX05 (trastuzumab)
Drug: Paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2018-06-14

Last Posted Date: 2022-01-14

Lead Sponsor: Tanvex BioPharma USA, Inc.

Target Recruit Count: 809

Registration Number: NCT03556358

Locations: 🇨🇱
Tanvex Investigational Site 4002, Viña Del Mar, Chile
🇧🇾
Tanvex Investigational Site 1007, Babruysk, Mogilev Region, Belarus
🇧🇾
Tanvex Investigational Site 1008, Lesnoy, Minsk Region, Belarus

and more 143 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy